Urology Cancer Recruitment Overview

Dr Mohini Varughese Consultant Clinical Oncologist

April 2019




Business Intelligence Unit

Urology (Bladder, Prostate & Renal) - National ABF Category

RecruitmentDate_FinancialYear	FY1617	7						FY1718	3						FY1819								
LCRN	Com.	Int.		Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	C	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	C		Large Scale	Total	Adj. for Pop. Rank		
East Midlands	6	3	172	143	88	466	1	4 1	8	235	167	47	467	7 12	2 79	9 1	95	102	35	411	13		
Eastern	6	4	191	528	150	933	1	9 4	1	145	230	110	526	6 10	36	3 2	25	182	112	555	8		
Greater Manchester	96	6	183	1426	98	1803	1	1 7	3	231	612	71	987	7 2	2 38	3 1	56	531	32	757	2		
Kent, Surrey and Sussex	7	1	301	1081	97	1550)	3 1	D	203	638	137	988	3 6	5 16	5 1	71	294	98	579	9		
North East and North Cumbria	67.	2	261	247	54	1234	l i	2 37	3	213	139	48	3 773	3 3	493	3	81	47	9	630	5		
North Thames	12	4	399	708	145	1376	; 1	0 18	7	523	357	74	114	1 7	134	4 2	256	197	30	617	12		
North West Coast	8	5	148	10	97	340	1	5 1	D	154	92	39	295	5 14	4 30) 1	83	109	14	336	14		
North West London	30	4	104	95	22	525	5	8 2	1	117	51	17	206	6 13	3 21	1 4	24	25	4	474	4		
South London	8	6	405	264	334	1089)	4 8	5	339	284	467	1176	5 1	79	9 3	31	298	381	1089	1		
South West Peninsula	7.	4	171	305	49	599		7 4	2	94	219	34	389	9 9	12	2 1	34	297	34	477	6		
Thames Valley and South Midlands	3.	4	134	560	14	742		5 2	5	57	442	6	531	1 5	5 22	2	76	281	16	395	7		
Wessex	18	6	386	226	7	805		6 10	3	186	201	6	496	6 8	3 190) 1	71	274	2	637	3		
West Midlands	9	1	414	142	199	846	1	2 4	3	243	182	145	613	3 11	1() 1	35	125	49	319	15		
West of England	4	7	125	46	137	355	i 1	3 1	5	73	19	55	5 162	2 15	5 17	7	84	142	59	302	10		
Yorkshire and Humber	6	1	500	554	57	1172	2 1	1 1	5	379	857	63	3 1314	4 4	10	1 3	37	135	27	600	11		



Urology (Bladder, Prostate & Renal) – Trust Recruitment Overview






5

Sub-specialty: Bladder Cancer - National ABF Category

RecruitmentDate_FinancialYear	FY1617	7					FY1718	FY1718									FY1819								
LCRN	Com.	Int.	0	Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.	(Obs.	Large Scale	Total		Adj. for Pop. Rank	Com.	Int.		Obs.	Large Scale	Total	Adj. for Pop. Rank			
East Midlands		9	62	137	C	208	3 1	1	9	66	136	6	0	211	. 9	5	8	47	44	1	0 1	49	6		
Eastern	1	1	26	170	C	207	10	0 1	6	35	88	3	0	139	10		3	26	59		0	88 1	0		
Greater Manchester	1 3	8	16	715	C	739		2	9	26	402)	0	437	3		1	22	126		0 1	49	4		
Kent, Surrey and Sussex		2	33	937	C	972	2 4	4	5	38	500)	0	543	5		1	7	98		0 1	D6	9		
North East and North Cumbria	57	0	128	201	C	899) -	1 35	7	94	50)	0	501	1	36	4	12	16	1	0 3	92	1		
North Thames	5	4	32	315	C) 401	9	9 11	7	95	131		0	343	8	3	6	53	27		0 1	16 1	3		
North West Coast	2	7	38	0	C) 65	5 13	3	8	27	70)	0	105	12		8	10	81		0	99	7		
North West London	30	3	49	79	C) 431		5 1	2	15	44	l.	0	71	11	1	8	5	24	3	0	47 1	1		
South London	1	9	20	0	C) 39	14	4 1	3	27	40)	0	80	13		8	43	17	1	0	58 1	2		
South West Peninsula		0	38	289	C	327	1	7	2	20	175	5	0	197	6		3	7	46		0	56	8		
Thames Valley and South Midlands		3	23	478	C	504	1 3	3 2	2	19	343	3	0	384	2	1	5	25	183		0 2	23	2		
Wessex	18	2	54	169	C	405	5 6	5 9	9	42	78	3	0	219	7	9	6	24	21	3	0 1	41	3		
West Midlands		3	31	68	C) 102	2 12	2	7	13	94	ļ.	0	114	14		1	12	49		0	62 1	4		
West of England		2	22	0	C) 24	1	5	2	29	C)	0	31	15		1	20	0		0	21 1	5		
Yorkshire and Humber	1	6	95	528	C	639) 8	8	3	93	689)	0	785	4	9	7	41	132		0 2	70	5		



Sub-specialty: Bladder Cancer – Trust Recruitment Overview





Bladder: A priority to enhance enrollment to trials

• NMIBC

- Immunotherapy for high risk disease
- Will require close liaison between oncology and urology (additional resource for oncology ++)

• MIBC

- Quality of Life After Bladder Cancer (Q-ABC) easy win
 - Any patient undergoing potentially curative radical treatments for confirmed muscle invasive bladder cancer by either surgery or radiotherapy
- Bladder PATH
 - Image Directed Redesign of Bladder Cancer Treatment Pathways
 - RAIDER (Dose escalated, adaptive RT, to complete recruitment


Bladder

- MIBC
 - Neoadjuvant studies of standard chemo +/- immunotherapy prior to cystectomy
 - RAD-IO
 - Radical CRT with durvalumab
- Metastatic disease
 - ATLANTIS (MAMs): maintenance vs placebo of rucaparib/ cabozanotainb/ Enzalutamide
 - FORT: randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinumcontaining chemotherapy

Sub-specialty: Prostate Cancer - National ABF Category

RecruitmentDate_FinancialYear	FY1617	7						FY1718	3						FY1819								
LCRN	Com.	Int.		Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.		Obs.	Large Scale	Total	Adj. for Pop. Rank	Com.	Int.		Obs.	Large Scale	Total	Adj. for Pop. Rank		
East Midlands	54	4	94	5	88	241	1.	4	4	156	30	47	237	7 13	3 1	3	134	58	35	240	12		
Eastern	49	9	141	354	150	694	1 :	3 1	3	101	139	110	363	3 6	6 1	8	152	121	112	403	7		
Greater Manchester	63	3	161	710	98	1032	2	1 2	4 2	202	205	71	502	2 2	2 1	5	119	395	32	561	3		
Kent, Surrey and Sussex	6	7	256	143	97	563	3 (8	2 *	163	137	137	439	9 4	1	7	164	195	98	464	8		
North East and North Cumbria	102	2	118	32	54	306	6 10	D 1	5	112	86	48	3 261	1 8	3 12	2	67	29	9	227	9		
North Thames	4(D	339	381	145	905	5 4	4 3	9 3	391	211	74	1 715	5 3	3 5	8	180	155	30	423	10		
North West Coast	50	D	98	10	97	255	5 1:	3	1	125	22	39	9 187	7 15	5	7	152	28	14	201	14		
North West London	1	1	51	0	22	2 74	L 15	5	5	100	1	17	123	3 11	1	0	416	1	4	421	2		
South London	53	3	368	212	334	967	7 2	2 5	7 :	300	143	467	967	7 1	1 6	7	276	229	381	953	1		
South West Peninsula	63	3	119	16	49	247	7 (9	3	69	44	34	150) 10)	1	127	251	34	413	4		
Thames Valley and South Midlands	29	9	111	79	14	233	3 11	1	3	38	91	6	5 138	3 12	2	1	50	93	16	160	11		
Wessex	1	2	315	57	7	381		5	0 .	137	119	6	6 262	2 5	5 8	8	144	247	2	481	5		
West Midlands	83	3	380	73	199	735	5 (6 3	6 3	229	87	145	5 497	7 9	9	5	122	76	49	252	15		
West of England	39	9	86	46	137	308	3	7	8	39	19	55	5 121	1 14	1	8	64	142	59	273	6		
Yorkshire and Humber	39	9	366	23	57	485	5 13	2	8 3	274	165	63	3 510	7 0	7	3	258	0	27	288	13		

Sub-specialty: Prostate Cancer – Trust Recruitment Overview





Prostate

Non metastatic

- STAMINA Supported exercise TrAining for Men with pros-tate caNcer on Androgen deprivation therapy
- PIVOTAL Boost
- ADD ASPIRIN
- POPs
- PACE International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer Hormone sensitive locally advanced/ metastatic
- Hormone Sensitive prostate cancer
 - STAMPEDE (currently oestrogen patch vs metformin)
 - Future arms to involve radium, ? SABR to 5 metastatic sites

Prostate

- mCRPC
 - ACE (measurement of cognitive function Enzalutamide vs Abiraterone)
 - CTC stop (due to be stopped early)
 - TOPARP
 - Immunotherapy studies
 - Keynote 010 pembrolizumab + olaparib vs abi/ enza
 - Key note 641 pembrolizumab + enza vs placebo + enzalutamide
 - MAESTRO: Molecular stratification profiling protocol in metastatic Castration Resistant Prostate Cancer (mCRPC)
 - PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering from Metastatic Prostate Cancer

Sub-specialty: Renal Cancer - National ABF Category

RecruitmentDate_FinancialYear	FY1617									FY1718										FY1819							
LCRN	Com.	Int.	Ob		arge Scale	Total	Adj. for Pop. Ran	k C	om.	Int.	C	bs.	Large Scale	То		Adj. for Pop. Rank	Com.	Int.		Obs.	Large Scale	Total		dj. for op. Rank			
East Midlands	. B	0	16	1	0) 1		12	5		13	-		0	19		8	В	14	0		0	22	9			
Eastern		4	24	4	0) 3	32	9	12		9	3	3	0	24	5	15	5	47	2		0	64	2			
Greater Manchester	2	.5	6	1	0) 3	32	4	40		3	5	5	0	48	3	22	2	15	10		0	47	3			
Kent, Surrey and Sussex		2	12	1	0) 1	5	13	3		2	-		0	6	13	8	В	0	1		D	9	14			
North East and North Cumbria		0	15	14	0) 2	29	5	1		7	3	3	0	11	11	100	7	2	2		0	11	10			
North Thames	3	0	28	12	0) 7	0	2	31		37	15	5	0	83	4	4(D	23	15		0	78	4			
North West Coast		8	12	0	0) 2	20	11	1		2	()	0	3	14	1	5	21	0		0	36	5			
North West London		0	4	16	0) 2	20	6	4		2	6	6	0	12	6		3	3	0		D	6	13			
South London	1	4	17	52	0) 8	33	1	16		12	101		0	129	1	4	4	12	52		0	68	1			
South West Peninsula	1	1	14	0	0) 2	25	3	37		5	()	0	42	2	8	8	0	0		D	8	11			
Thames Valley and South Midlands		2	0	3	0)	5	14	1		0	8	3	0	9	10	(6	1	5		0	12	8			
Wessex		2	17	0	0) 1	9	10	4		7	4	1	0	15	7	(6	3	6		0	15	7			
West Midlands		5	3	1	0)	9	15	0		1			0	2	15	4	4	1	0		0	5	15			
West of England		6	17	0	C) 2	23	7	5		5	()	0	10	9	8	В	0	0		D	8	12			
Yorkshire and Humber		6	39	3	0) 4	18	8	4		12	3	3	0	19	12	1.0	1	38	3		0	42	6			

CRN;SWP priorities

- Enhance recruitment to radiotherapy trials
 - Funding to follow for each centre
- Trials to consider opening at each site
 - QABC, Bladder PATH (operating centres), RAD-IO, ATLANTIS,
 - STAMINA, PIVOTAL Boost, PACE
 - RAMPART
- Enhance cross trust referral
 - e.g. TOPARP,
 - NAC immunotherapy studies at cystectomy centres
 - Prostate immunotherapy studies
 - Immunotherapy for NIBC?



